单次利妥昔单抗治疗原发免疫性血小板减少症的疗效及安全性
Safety and efficacy of single dose rituximab in primary immune thrombocytopenia

DOI: 10.6040/j.issn.1671-7554.0.2018.210

Keywords: 原发免疫性血小板减少症,利妥昔单抗,疗效,
Rituximab,Immune thrombocytopenia,Efficacy

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia[J]. Eur J Haematol, 2013, 90(6): 494-500.
[2]	Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura[J]. Haematologica, 2008, 93(6): 930-933.
[3]	Cooper N, Stasi R, Cunninghamrundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura[J]. Br J Haematol, 2004, 125(2): 232-239.
[4]	Grace RF, Bennett CM, Ritchey AK, et al. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia[J]. Pediatr Blood Cancer, 2012, 58(2): 221-225.
[5]	Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia[J]. Eur J Haematol, 2010, 85(4): 329-334.
[6]	Garcia-Suarez J, Prieto A, Reyes E, et al. The clinical outcome of autoimmune thrombocytopenic purpura patients is related to their T cell immunodeficiency[J]. Br J Haematol, 1993, 84(3): 464-470.
[7]	姚春花. 小剂量利妥昔单抗在原发免疫性血小板减少症患者中的应用[J]. 中外医学研究, 2016, 14(12): 162-164.
[8]	Cervinek L, Cerná O, Caniga M, et al. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice[J]. Int J Hematol, 2012, 96(5): 594-599.
[9]	Khellaf M, Charlesnelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients[J]. Blood, 2014, 124(22): 3228-3236.
[10]	Mahévas M, Ebbo M, Audia S, et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia[J]. Am J Hematol, 2013, 88(10): 858-861.
[11]	Ghanima W, Godeau B, Cines DB, et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment[J]. Blood, 2012, 120(5): 960-969.
[12]	Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia(ITP)[J]. J Clin Med, 2017, 6(2): 16-37.
[13]	Cines DB, Cuker A, Semple JW. Pathogenesis of immune thrombocytopenia[J]. Presse Med, 2014, 43(2):49-59.
[14]	刘月波, 周泽平, 杨红, 等. 小剂量美罗华治疗原发免疫性血小板减少症的临床疗效观察[J]. 昆明医科大学学报, 2012, 33(11):99-101. LIU Yuebo, ZHOU Zeping, YANG Hong, et al. Efficacy of low-dose rituximab for patients with immune thrombocytopenia[J]. Journal of Kunming Medical University, 2012, 33(11): 99-101.
[15]	Zaja F, Volpetti S, Chiozzotto M, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia[J]. Am J Hematol, 2012, 87(9): 886-889.
[16]	隋涛, 张磊, 周泽平,等. 两种小剂量利妥昔单抗治疗方案治疗原发免疫性血小板减少症疗效比较[J]. 中华血液学杂志, 2011, 32(9): 583-586. SUI Tao, ZHANG Lei, ZHOU Zeping, et al. Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia[J]. Chinese Journal of Hematology, 2011, 32(9): 583-586.
[17]	Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura[J]. Blood, 2001, 98(4): 952-957.
[18]	British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol, 2003, 120(4): 574-596.
[19]	中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志,2016,37(2):89-93.
[20]	Brah S, Chiche L, Fanciullino R, et al. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey[J]. Ann Hematol, 2012, 91(2):279-285.
[21]	郭素丽, 陈娜飞, 魏秋平,等. 小剂量与标准剂量利妥昔单抗治疗老年慢性难治性免疫性血小板减少症的临床研究[J]. 实用医学杂志, 2013, 29(13): 2197-2198.
[22]	Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia[J]. Blood, 2013, 121(11): 1976-1981.
[23]	李丹, 胡俊, 刘顺妹,等. 标准剂量与小剂量利妥昔单抗治疗难治性免疫性血小板减少症的临床研究[J]. 医学综述, 2015(3):571-573. LI Dan, HU Jun, LIU Shunmei, et al. Clinical study of standard dose and small dose of rituximab treating refractory immune thrombocytopenia[J]. Medical Recapitulate, 2015(3): 571-573.
[24]	Auger S, Duny Y, Rossi JF, et al. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis[J]. Br J Haematol, 2012, 158(3): 386-398.
[25]	Reboursiere E, Fouques H, Maigne G, et al. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles[J]. Int J Hematol, 2016, 104(1): 85-91.

Full-Text